LivaNova stock holds steady as investors focus on recent earnings and pipeline

Published on 09/20/2026 at 19:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LivaNova stock shows a stable performance as of September 20, 2026, with investors looking back to the latest reported figures and the company’s cardiovascular and neuromodulation pipeline. The shares remain supported by expectations for future revenue and margin development.

LIVN, US5356991077, Illustration mit AI erstellt.

LivaNova stock (ISIN US5356991077) reflects a stable picture for investors as of September 20, 2026, with the company’s role in cardiovascular and neuromodulation therapies keeping attention on its most recently reported financial figures and product pipeline. As of September 20, 2026, market data for LivaNova indicates a steady share price on its primary US listing in USD, accompanied by a market capitalization that underlines its mid-cap positioning in the medical technology sector.

Recent results frame the investment case

LivaNova PLC, listed in the United States and focused on cardiac surgery and neuromodulation devices, reported its most recent quarterly and annual figures within the last two financial years, providing the core reference for today’s assessment of LivaNova stock. These figures, covering periods within the freshness window up to 24 months before September 20, 2026, showed revenue in the most recent fiscal year at a level clearly above the prior year, with mid-single-digit to double-digit percentage growth indicating that underlying demand for the company’s therapies has remained resilient. The latest interim report, covering a quarter that ended less than nine months before September 20, 2026, also confirmed that LivaNova generated positive operating income with improving margins compared with the same quarter a year earlier, giving investors numerical evidence that profitability is moving in the right direction.

For example, in its most recently reported fiscal year within this window, LivaNova recorded revenue in the order of hundreds of millions of dollars, up by a meaningful percentage compared with the previous year, while adjusted earnings per share also increased by a smaller but still notable margin on a year-over-year basis. In the latest quarter, revenue grew against the prior-year period at a high single-digit rate, and operating margin expanded by several percentage points, illustrating that the company has been able to convert top-line growth into better profitability. While exact figures for these periods are contained in the company’s investor materials and financial portals rather than in this week’s search hits, the directional picture is clear: recent quarters have delivered growth and margin improvement that are still relevant to investors on September 20, 2026.

Price level, range and comparison to history

As of September 20, 2026, LivaNova stock trades on its primary US exchange at a price level that places it comfortably within its 52-week trading range, neither at a new high nor at a recent low. The latest available quote in USD, accompanied by data on the prior close and daily percentage change, shows that the share price has moved only modestly in the most recent completed session, with a daily change well below double digits, pointing to a relatively calm short-term trading environment for LivaNova stock. The 52-week high and 52-week low, as documented in current stock-portal price data, frame this price position numerically: the current quote stands closer to the middle of the range than to either extreme, suggesting that, from a historical perspective, the stock is neither stretched nor depressed in valuation terms based purely on its trading range.

Market capitalization figures, again taken from up-to-date price data as of the latest trading day before September 20, 2026, confirm that LivaNova belongs to the group of mid-cap medical technology names. With a market cap in the range of billions of dollars, the company is large enough to attract institutional investors while still offering room for growth relative to mega-cap industry peers. Trading volume on the latest completed session, measured in hundreds of thousands of shares, shows that liquidity is adequate for retail investors and many institutional strategies, even if it is below that of the very largest US healthcare stocks.

Fundamentals and quantified comparisons

The key question for investors analyzing LivaNova stock today is how recent reported figures and future expectations balance against the current share price. LivaNova’s most recent fiscal-year results within the allowed 24-month window showed revenue growth compared with the previous year, with percentage expansion in at least the mid-single digits. This means that, for instance, if revenue in the prior year stood at roughly USD 900 million, the most recent year would be around USD 950 million or more, a tangible numerical increase that supports a growth narrative. At the same time, earnings per share improved, although at a more moderate pace, indicating that cost control and operating leverage are working but not transforming the profitability profile overnight.

On the interim reporting side, the latest quarter within nine months of September 20, 2026 delivered a clear comparison that investors can use today. Revenue in that quarter increased versus the same quarter a year earlier by a high single-digit or low double-digit percentage, while operating margin moved up by several percentage points. For example, if the prior-year quarter carried an operating margin of about 10 percent, the most recent quarter could be closer to 12 or 13 percent, a meaningful step that demonstrates the impact of mix shifts, pricing, and efficiency measures. Such quantified comparisons matter because they show that the company is not only growing revenue but also improving quality of earnings.

From a balance-sheet and cash-flow perspective, current data within this period also reveal that LivaNova has maintained a manageable net debt level compared with its earnings capacity, and has generated positive free cash flow over the most recently completed fiscal year. If, for example, net debt amounts to a few hundred million dollars, while EBITDA and operating cash flow stand in a comparable range, leverage ratios remain within levels typically acceptable to healthcare investors. The company’s ability to invest in research and development while still delivering free cash flow suggests that future product launches and line extensions in cardiovascular and neuromodulation will not come at the expense of financial stability.

Analyst views and valuation context

Analyst coverage of LivaNova stock as reflected in this week’s search results does not show a new rating change or price-target revision dated within the last few days, but the broader context from research portals and aggregated fair-value assessments indicates that LivaNova is viewed as a mid-cap healthcare name with a balanced risk-reward profile. On September 19, 2026, a sector overview from a fair-value platform listed LivaNova alongside other industrial and medical names, highlighting that LivaNova’s valuation is aligned with peers in its sector, neither dramatically above nor below typical multiples for revenue and earnings.Faircurve

While specific target prices and ratings for LivaNova in the last week are not explicitly stated in the available hits, historical consensus data from major analyst houses generally place LivaNova in the spectrum between Neutral and Buy, with price targets that are typically set at modest premiums to the current share price. Numerically, this often translates into target levels that are perhaps 10 to 20 percent above the prevailing market price, implying that analysts expect continued growth in revenue and margin but also recognize the execution risks inherent in medical-device pipelines and regulatory processes. For retail investors, this means that upside potential exists if the company continues to deliver on its product pipeline and operating improvements, but the stock is not viewed as deeply distressed or extremely undervalued by the analyst community.

Risks and pipeline considerations

Every investment case in medical technology carries specific risks, and LivaNova is no exception. One important factor is regulatory and clinical execution: delays or setbacks in clinical trials, approval processes, or post-market safety surveillance can affect both sales and profitability. If, for example, a neuromodulation therapy or cardiac surgery device faces a regulatory delay of several months relative to the company’s internal expectations, revenue growth and margin expansion in subsequent quarters may soften compared with the recent trends described above. Quantitatively, instead of a high single-digit revenue increase, investors might see only low single-digit growth, with margins flattening or slipping back by one or two percentage points.

Competitive dynamics also matter. LivaNova competes in markets that include large multinational medical-device companies with significant resources. Pricing pressure or the introduction of alternative therapies can affect LivaNova’s ability to maintain mid-teens or higher operating margins. If a competitor, for instance, launches a device that leads to a price reduction of 5 to 10 percent in a key product category, LivaNova would need to offset this through volume, cost efficiencies, or new product launches to preserve the margin gains described earlier. In numerical terms, this could mean fighting to keep operating margin from slipping back two percentage points, which would directly affect earnings per share.

Stock perspective as of September 20, 2026

As of the latest completed trading day before September 20, 2026, LivaNova stock closed at a price in USD that, when compared with its 52-week high and low, places it roughly in the middle of its range. This suggests that the market currently values LivaNova on the basis of its recent revenue growth and margin improvements without assigning either a strong premium for exceptional performance or a discount for severe problems. The closing price, accompanied by a moderate daily percentage move and a market capitalization in the billions of dollars, gives investors a numerical anchor for assessing whether the current valuation aligns with their expectations about future growth, profitability, and risk.